THE EFFECT OF COMBINED α1-ADRENERGIC BLOCKERS AND PDE-5 INHIBITORS THERAPY ON IPSS, IIEF-5, QMAX AND PVR PATIENTS BPH WITH LUTS AND ERECTILE DYSFUNCTION

Muhammad Ridha, Sunaryo Hardjowijoto, Johan Renaldo

Abstract


Purpose: Assess the efficacy of combined α1-adrenergic blocker (tamsulosin 0,4 mg) and PDE5 inhibitor (tadalafil 5 mg) therapy compared to tadalafil or tamsulosin alone in treating patient BPH with LUTS and ED.

 

Material and methods: A randomised, double blind experimental study assessed 36 sexually active men with ED and LUTS suggestive of BPH.  All patients were randomized to 3 groups: tamsulosin 0,4 mg (n=12), tadalafil 5mg (n=12), and combination of tamsulosin 0,4 mg and tadalafil 5 mg (n= 12), once daily for 6 weeks.  Changed in IPSS scores and QoL index, IIEF-5 scores, Qmax, PVR and blood pressure were assessed and compared to baseline. Complication and serious adverse event were also monitored.  Outcomes were assessed using ranked analysis of variance (ANOVA) and Kruskall-Wallis depends on data distribution and homogenity.

Results:  Tamsulosin 0,4 mg once daily for 6 weeks were significantly improved IPSS score and QoL index and Qmax from baseline.  Tadalafil 5 mg once daily for 6 weeks were significantly improved IPSS score, QoL index and IIEF-5 index from baseline. Combined tamsulosin and tadalafil therapy were significantly improved IPSS score, QoL index, IIEF-5 index and Qmax from baseline.  Significantly better improvement on IIEF-5 dan Qmax from baseline were observed on the combination of tamsulosin and tadalafil compared to monotherapy with tamsulosin or tadalafil after 6 weeks in  patients BPH with LUTS and erectile dysfunction. There was no significant decreased in systolic and diastolic blood pressure from combined treatment compared to single treatment.

Conclusions: Combined tamsulosin and tadalafil therapy was significantly better in improving IIEF a

Objective: Assess the efficacy of combined α1-adrenergic blocker (tamsulosin 0.4 mg) and PDE5 inhibitor (tadalafil 5 mg) therapy compared to tadalafil or tamsulosin alone in treating patient Benign Prostate Hyperplasia (BPH) with lower urinary tract symptom (LUTS) and erectile dysfunction (ED). Material & methods: A randomised, double blind experimental study assessed 36 sexually active men with ED and LUTS suggestive of BPH. All patients were randomized to 3 groups: tamsulosin 0.4 mg (n=12), tadalafil 5mg (n=12), and combination of tamsulosin 0.4 mg and tadalafil 5 mg (n= 12), once daily for 6 weeks. Changed in IPSS scores and QoL index, IIEF-5 scores, Qmax, PVR and blood pressure were assessed and compared to baseline. Complication and serious adverse event were also monitored. Outcomes were assessed using ranked analysis of variance (ANOVA) and Kruskall-Wallis depends on data distribution and homogenity. Results: Tamsulosin 0.4 mg once daily for 6 weeks were significantly improved IPSS score, QoL index and Qmax from baseline. Tadalafil 5 mg once daily for 6 weeks were significantly improved IPSS score, QoL index and IIEF-5 index from baseline. Combined tamsulosin and tadalafil therapy were significantly improved IPSS score, QoL index, IIEF-5 index and Qmax from baseline. Significantly better improvement on IIEF-5 dan Qmax from baseline were observed on the combination of tamsulosin and tadalafil compared to monotherapy with tamsulosin or tadalafil after 6 weeks in  patients BPH with LUTS and erectile dysfunction. There was no significant decreased in systolic and diastolic blood pressure from combined treatment compared to single treatment. Conclusion: Combined tamsulosin and tadalafil therapy was significantly better in improving IIEF and Qmax, but not significantly better in improving IPSS and PVR compared to monotherapy with tamsulosin or tadalafil alone. Combined therapy was well tolerated without serious adverse effect.

nd Qmax, but not significantly better in improving IPSS and PVR compared to monotherapy with tamsulosin or tadalafil alone.  Combined therapy was well tolerated without serious adverse effect.


Keywords


BPH; LUTS; erectile dysfunction; α1-adrenergic blocker; PDE-5 inhibitor

Full Text:

PDF

References


Roehrborn CG, McConnell JD. Benign prostatic hyperplasia: Etiology, pathophysiology, epidemiology and natural history. In Walsh PC, Retik AB, Vaughan ED Jr., Wein A, eds. Campbell-Walsh Urology, 10th ed. Philadelphia: Elsevier Saunders; 2012.

Hardjowijoto S. Panduan Petalaksanaan (Guidelines) Benign Prostatic Hyperplasia di Indonesia. Ikatan Ahli Urologi Indonesia (IAUI); 2003.

Marks LS, Roehrborn CG, Wolford E, Wilson TH. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of transition zone index in predicting treatment response. J Urol. 2007; 177: 1408–13.

Roehrborn CG, Bartsh G, Kirby R. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: A comparative, international overview. Urology; 58: 642–50.

Roehrborn CG. Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitors. In Reviews in Urology. 2004; 6(3).

Bang-Ping Jiann MD. Association of lower urinary tract symptoms/benign prostatic hyperplasia with sexual dysfunction. Incont Pelvis Floor Dysfunct. 2008; 2(4): 151–5.

Feldman HA, Goldstein I, Krane RJ. Impotence and its medical and psychosocial correlates: Results of the Massachusetts male ageing study. J Urol. 2004; 151(1): 54–56.

Seftel AD. Erectile dysfunction a decade later: Another paradigm shift. J Urol. 2006; 176: 10–11.

Lewis R, Hatzuchristou D, Mc Kinlay J. Epidemiology and natural history of erectile dysfunction. In Walsh PC, Retik AB, Vaughan ED Jr., Wein A, eds. Campbell-Walsh Urology, 10th ed. Philadelphia: WB Saunders-Elsevier; 1999.

Chungyu Wang. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol. 2010; 20: 49–54.

Burnett, Arthur L. Erectile dysfunction. J Urol. March 2006; 175: S25–31.

Rosen R, Altwein J, Boyle. Lower urinary tract symptoms and male sexual dysfunction: The Multi National Survey of the Aging Male (MSAM-7). Eur Urol. 2003; 44: 637.

Kaplan Steven A, Ricardo R Gonzales. Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms. In Review in Urology. 2007; 9(2).

Rajeev Kumar, Ajay Nehra. α-blocker use is associated with decreased risk of sexual dysfunction. Published in National Institute of Health. Urology. July 2009; 74(1): 82–87.

Kevin T. McVarry, Claus G. Roehrborn. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. April 2007; 177: 1401–7.

Kirby R, Lepor H. Evaluation and nonsurgical management of benign prostatic hyperplasia. In Walsh PC, Retic AB Vaughan ED Jr., Wein A, eds. Campbell-Walsh Urology, 10th ed. Philadelphia: Elsevier Saunders.

Tuomo Nieminen, Teuvo LJ Tammela, Tiit Kööbi, Mika Kähönen. The effects of tamsulosin and sildenafil in separate and combined regimens on detailed hemodynamics in patients with benign prostatic enlargement. J Urol. Desember 2006; 176: 2551–6.

Yudanto BH, Hardjowijoto S, Soetojo. Pemberian kombinasi tamsulosin dan solifenacin pada pasien BPH dengan LUTS tanpa komplikasi di Indonesia (evaluasi pada frekuensi, nokturia, Qmax dan PVR) penelitian eksperimental pre dan post kontrol. Department of Urology, Faculty of Medicine/Universitas Airlangga, Soetomo Hospital Surabaya; 2010.

L Liu, S Zheng, P Han, Q Wei. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review and meta-analysis. Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China Urology. 2011; 77: 123–9.

Hartmut Porst, Edward D. Kim. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptom suggestive of benign prostatic hyperplasia: Result of an international randomized, double-blind, placebo-controlled trial. Eur Urol. 2011; 60: 1105–13.

Matthias Oelke, Francois Giuliano. Effects of tadalafil or tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia and on erectile dysfunction: Results from an international, double-blind, placebo-controlled trial. Eur Urol. 2012; 61: 917–25.

Mario Gracci, Corona Giovanni, Salvi Matteo. A systematic review and meta analysis of the use of phosphodiesterase type-5 inhibitors (PDE-5-IS) for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). J Urol. May 2012; 187(4S) Supp: 21.

Lee JY, Park SY, Jeong TY. Combined tadalafil and α-blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: A multicenter, prospective study. J Androl; 2011.

Donatucci CF, Brock GB, Goldfischer ER. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A 1-year, open-label extension study. BJU Int. 2011; 107: 1110–6.

Robert A. Kloner, Graham Jackson. Interaction between the phosphodiesterase-5 inhibitor, tadalafil and α-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol. November 2004; 172: 1935–40.

Ricardo Reges, Rommel Regadas. The association of tamsulosin and daily tadalafil for the treatment of lower urinary tract symptoms is safe and effective? J Urol. May 2012; 187(4S) Supp: 21.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.